Interestingly, high COX-2 expression was significantly associated with poor patient outcome in basal-like breast cancer tumors represented as shorted OS, DMFS and AE free survival (Hazard Ratio (HR), 1.92; 0.99 to 3.71; p = 0.049); (HR, 1.87; 1.04 to 3.35; p = 0.034), (HR = 1.36; 1.05 to 1.75; P = 0.0193), (HR = 1.30; 0.99 to 1.71; P = 0.05) respectively in these patients (Fig. 1i,j). This evidence concerns the gene PTGS2 and breast cancer.